{"id":51352,"date":"2025-12-18T13:09:53","date_gmt":"2025-12-18T05:09:53","guid":{"rendered":"https:\/\/flcube.com\/?p=51352"},"modified":"2025-12-18T13:09:53","modified_gmt":"2025-12-18T05:09:53","slug":"sanofi-adel-alzheimers-deal-targets-phase-1-adel-y01-antibody","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51352","title":{"rendered":"Sanofi Adel Alzheimer&#8217;s Deal Targets Phase 1 ADEL-Y01 Antibody"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced a license agreement with South Korean biotech <strong>Adel<\/strong> to gain exclusive global rights to <strong>ADEL-Y01<\/strong>, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for <strong>Alzheimer&#8217;s disease<\/strong>, in a deal valued at up to <strong>$1.04 billion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Sanofi (NASDAQ: SNY) + Adel (South Korea)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>ADEL-Y01 (Phase\u202f1 antibody therapy)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 80 million cash<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD 1.04 billion in milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on future sales<\/td><\/tr><tr><td><strong>Intellectual Property<\/strong><\/td><td>Exclusive global access + backup compounds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adel-y01-asset-profile\">ADEL-Y01 Asset Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Monoclonal antibody<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Tau protein acetylated at lysine\u2011280 (acK280)<\/td><\/tr><tr><td>**Mechanism<\/td><td>Selectively binds pathological tau, preventing neurofibrillary tangle formation<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase\u202f1 clinical trials<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First\u2011in\u2011class potential for Alzheimer&#8217;s disease<\/td><\/tr><tr><td><strong>Pipeline<\/strong><\/td><td>Includes undisclosed backup compounds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-context\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer&#8217;s Burden<\/strong>: Global market projected at <strong>$12 billion<\/strong> by 2030; tau\u2011targeted therapies represent next\u2011generation approach<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Existing drugs (aducanumab, lecanemab) target amyloid; tau pathway offers complementary mechanism<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage<\/strong>: ADEL-Y01 is among the first selective acK280 tau antibodies entering global development<\/li>\n\n\n\n<li><strong>Sanofi&#8217;s Neuroscience Push<\/strong>: Bolsters pipeline in neurodegenerative diseases; leverages global clinical and commercial infrastructure<\/li>\n\n\n\n<li><strong>Adel&#8217;s Validation<\/strong>: Deal validates Korean biotech innovation and provides non\u2011dilutive funding for broader pipeline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-path\">Development &amp; Commercialization Path<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202f1 Focus<\/strong>: Safety, target engagement, and biomarker endpoints in early Alzheimer&#8217;s patients<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Sanofi to lead all development, regulatory, and commercial activities worldwide<\/li>\n\n\n\n<li><strong>Milestone Triggers<\/strong>: Payments tied to Phase\u202f2 initiation, Phase\u202f3 completion, and regulatory approvals across major markets<\/li>\n\n\n\n<li><strong>Launch Timeline<\/strong>: Potential market entry <strong>2029\u20112030<\/strong> if clinical success is demonstrated<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ADEL-Y01 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51358,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4513,147],"class_list":["post-51352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adel","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Adel Alzheimer&#039;s Deal Targets Phase 1 ADEL-Y01 Antibody - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer&#039;s disease, in a deal valued at up to $1.04 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51352\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Adel Alzheimer&#039;s Deal Targets Phase 1 ADEL-Y01 Antibody\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer&#039;s disease, in a deal valued at up to $1.04 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51352\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T05:09:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Adel Alzheimer&#8217;s Deal Targets Phase 1 ADEL-Y01 Antibody\",\"datePublished\":\"2025-12-18T05:09:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1801.webp\",\"keywords\":[\"Adel\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51352#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51352\",\"name\":\"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1801.webp\",\"datePublished\":\"2025-12-18T05:09:53+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer's disease, in a deal valued at up to $1.04 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51352\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51352#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Adel Alzheimer&#8217;s Deal Targets Phase 1 ADEL-Y01 Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer's disease, in a deal valued at up to $1.04 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51352","og_locale":"en_US","og_type":"article","og_title":"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody","og_description":"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer's disease, in a deal valued at up to $1.04 billion.","og_url":"https:\/\/flcube.com\/?p=51352","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-18T05:09:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51352#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51352"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Adel Alzheimer&#8217;s Deal Targets Phase 1 ADEL-Y01 Antibody","datePublished":"2025-12-18T05:09:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51352"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51352#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","keywords":["Adel","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51352#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51352","url":"https:\/\/flcube.com\/?p=51352","name":"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51352#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51352#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","datePublished":"2025-12-18T05:09:53+00:00","description":"Sanofi (NASDAQ: SNY) announced a license agreement with South Korean biotech Adel to gain exclusive global rights to ADEL-Y01, a Phase\u202f1 antibody therapy targeting tau protein acetylated at lysine\u2011280 (acK280) for Alzheimer's disease, in a deal valued at up to $1.04 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51352#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51352"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51352#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","width":1080,"height":608,"caption":"Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51352#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Adel Alzheimer&#8217;s Deal Targets Phase 1 ADEL-Y01 Antibody"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51352"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51352\/revisions"}],"predecessor-version":[{"id":51359,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51352\/revisions\/51359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51358"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}